Study: NCT06019130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluoruracil during induction chemotherapy in all groups except of adults \> 25 years with metastatic disease at diagnosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine during induction chemotherapy in patients \> 25 years with metastatic disease at diagnosis

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: After induction therapy in all patients

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: After induction therapy in all patients

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: After induction therapy in all patients

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: After induction therapy in all patients

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: After induction therapy in all patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: In patients \< 26 years after end of radiochemotherapy for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: In patients \< 26 years after end of radiochemotherapy for 6 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes
Description: For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment